Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-17
SponsorSmith & Nephew, Inc.

About this trial

This prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients aged from 6 months to 17 years of age who are undergoing an in-office ear tube placement procedure (tympanostomy) using the Tula® System. The Registry will include up to 20 centers in the US and up to 200 patients for the initial evaluation.

The FDA-approved Tula System includes the Tula Iontophoresis System (IPS) with TYMBION™ otic anesthetic for local anesthesia of the ear drum and the Tula Tube Delivery System (TDS) for ear tube placement. Clinical research established the safety, efficacy and tolerability of this system for in-office procedures in the pediatric population. Patients will be treated and evaluated according to standard medical care. Outcome data is collected up to 6 months following extrusion or removal of their tube(s).

Eligibility criteria

Qualifiers

Patients ages 6 months through 17 years of age (inclusive) at time of tympanostomy in-office using the Tula® System

Patients who are candidates for in-office tube placement using the Tula System according to the System Instructions For Use

Disqualifiers

Patients who are wards are not included

Trial design

Treatments tested in this trial

  • Iontophoresis and tube placement

Treatment groups

200 Participants
are divided into 1 treatment group

Locations

6
Advanced ENT and Allergy40220, LouisvilleKentucky, United States
Regional Otolaryngology Head and Neck Associates08034, Cherry HillNew Jersey, United States
Rutgers Robert Wood Johnson Medical School08901, New BrunswickNew Jersey, United States
Columbia University Vagelos College of Physicians and Surgeons10032, New YorkNew York, United States

Sponsors and collaborators

Smith & Nephew, Inc.

Lead sponsor